Tilray Medical wins EU-GMP in-house testing approval at Portugal facility
Approval streamlines quality control for producer exporting medicinal cannabis from Portugal, as regulatory environment shows mixed signals.
FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0Tilray Medical has secured approval to conduct in-house EU-GMP testing at its Portugal facility, according to Cannabis Business Times. The authorization permits the company to perform its own quality assurance testing on-site rather than relying solely on external labs, potentially reducing production delays and improving operational efficiency for a major exporter from Portugal's medicinal cannabis sector.
The approval arrives amid a complex regulatory backdrop. Portugal has expanded its medical cannabis export footprint—shipments surpassed 66 tonnes in 2026—yet the country's regulator has faced criticism for processing delays. Recent coverage indicates Infarmed delays on license renewals have cost producers months, while Spain's GMP operators have begun capturing market share as Portugal stumbles. Tilray's in-house testing capability may help the company sidestep some bottlenecks.
Watch whether other Portuguese producers seek similar testing approvals, and whether this move signals confidence in Portugal's regulatory path or a defensive hedge as competing EU producers gain ground.
Original report: Cannabis Business Times ↗